Cefatrizine (BL-S-640) is an orally effective broad-spectrum cephalosporin antibiotic. Cefatrizine is used in cancer and bacterial infection research.
|Solubility (25°C)||DMSO ≥ 60 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 N Papantoniou, et al. Fetal Diagn Ther. Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution
 P J Santella, et al. Drugs Exp Clin Res. Cefatrizine: a clinical overview
 T Brotherton, et al. Antimicrob Agents Chemother. Susceptibility of Haemophilus influenzae type b to cefatrizine, ampicillin, and chloramphenicol
 P Actor, et al. Antimicrob Agents Chemother. Cefatrizine (SK&F 60771), a new oral cephalosporin: serum levels and urinary recovery in humans after oral or intramuscular administration--comparative study with cephalexin and cefazolin
 H C Neu, et al. Antimicrob Agents Chemother. Cefatrizine activity compared with that of other cephalosporins
|Related Apoptosis Products|
Misetionamide is an orally glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor with antineoplastic activity.
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models.
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.